- HK$163.45m
- HK$498.42m
- HK$336.11m
Annual cashflow statement for PuraPharm, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | ARS | ARS | ARS | ARS | |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -117 | -119 | -102 | -29.1 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 170 | 81.9 | 73.3 | 24.7 | — |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -118 | 77.1 | 60 | 53.8 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -14.5 | 88.5 | 79.6 | 104 | — |
| Capital Expenditures | -6.56 | -23.6 | -21.7 | -16.4 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 12.6 | -7.69 | 3.46 | 4.67 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 6 | -31.2 | -18.2 | -11.7 | — |
| Financing Cash Flow Items | -27 | -18.6 | -35.1 | -20.2 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -16 | -35.6 | -122 | -86.4 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -18.3 | 16.2 | -55.7 | -7.33 | — |